skip to main content

ESMO-MCBS — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateClinical Trials & StatisticsESMO-MCBSSCE Medical Oncology

A clinical trial reports results using the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS). The trial of a new drug for metastatic CRC shows a PFS improvement of 1.2 months (HR 0.82) with no OS data. This is scored as MCBS grade 1 (lowest). What does this grading mean for clinical adoption?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — ESMO-MCBS grade 1 indicates a low magnitude of clinical benefit — this informs payer decisions and clinical practice but does not prohibit use; it helps clinicians contextualise the incremental benefit relative to toxicity and cost

Explanation lettering: D = shown as A · A = shown as C · C = shown as D

The ESMO-MCBS scores new cancer treatments on a scale of 1-5 (palliative setting) or A-C (curative setting). Higher scores indicate greater magnitude of benefit. Grade 4-5 / A represent substantial benefit. The scale integrates treatment intent, endpoint (OS vs PFS), absolute benefit, HR, toxicity and quality of life. A low MCBS score does not prohibit use but informs resource allocation, reimbursement decisions and patient counselling about expected benefit. This is increasingly used alongside NICE ICER/QALY assessments.

Reference: ESMO-MCBS v1.1; Cherny et al Ann Oncol 2015; ESMO 2024 Guidelines